Skip to main content
LIFE

CELLINK

The world’s leading bioprinting company

IF WE deliver fully functioning organs on demand can we disrupt the way clinical testing and transplants are delivered?

The world has a shortage of organs suitable for human transplantation. In the US alone, as of March 2020 there were over 112,000 men, women, and children on the national transplant waiting list.
What if scientists could 3D-print new organs with a patients' own cells, eliminating the need for donated organs and the risk of rejection when organs are transplanted? That's exactly the path Cellink is pursuing: producing bioink and bioprinting technologies to enable researchers to 3D-print organs and tissue for applications that span industries, from pharmaceutical to cosmetic. 

Join the community

Bioprinted organs aim to raise transplant success

In 2016, CELLINK commercialized the world’s first bioink, a biomaterial innovation eight years in the making. That milestone was the first of many along the company’s journey to become the world’s leading bioprinting company; they currently have systems to optimize cell-based applications for more than 1,000 scientists across more than 55 countries.

Cellink

CELLINK was the first company to provide a standardized bio-ink product for sale over the internet. Researchers leverage its technologies to print liver, cartilage, skin tissues and more.

Cellink

POSITIVE IMPACT ON THE SOCIETY

GOAL 3: Good Health and well-being

Cellink ensures healthy lives and promotes well-being for all at every age.

SDG

But what if scientists could 3D-Print new organs with a patients' own celles, eliminating te need for donated organs and the risk of rejection? That's exactly the path Cellink is pursuing, producing bioink and bioprinting technologies to advance the field.

BENEFITS TO USE THE 3DEXPERIENCE® PLATFORM

The 3DEXPEIENCE platform enables Cellink to better predict and understand how living material will behave once it is bioprinted. The team can identify problems and virtually develop fixes before bioprinting an actual structure. By optimizing this process, Cellink can help academia and pharmaceutical companies efficiently bioprint organs and to test drugs in a unique, organ-like environment to accelerate research.


 

  • Erik  Gatenholm
    Erik Gatenholm
    CEO
  • Hector  Martinez
    Hector Martinez
    CTO
  • Gusten   Danielsson
    Gusten Danielsson
    CFO

Submit your project

Do you think your project is the next big thing?
Join the team !

Submit your project